In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

CR Bard buys SenoRx for $193mm in cash

Executive Summary

CR Bard Inc. (vascular, urology, oncology, and surgical specialty products) is acquiring all the outstanding shares of publicly traded SenoRx Inc. (breast cancer devices) for $11 each (an 11% premium), or a total of $193mm.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
    • Diagnostic Imaging Equipment & Supplies
      • MRI, NMR
      • X-ray
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash

Related Companies

UsernamePublicRestriction

Register